Sanofi (SNY) said Friday a European Medicines Agency committee recommended the approval of Cenrifki in the European Union to treat secondary progressive multiple sclerosis, a chronic autoimmune disorder.

The specific indication is for patients without relapses in the past two years.

The company said a final decision is expected in the coming months.